Cancer-Focused Biotech Syros Files For $69M IPO
Venture capital-backed biotechnology company Syros Pharmaceuticals Inc., which is developing cancer treatment drugs, on Friday filed plans for a $69 million initial public offering in a bid to raise funds for...To view the full article, register now.
Already a subscriber? Click here to view full article